Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAF
anti-epidermal growth factor receptor (EGFR) drugs
circulating tumor DNA (ctDNA)
colorectal cancer (CRC)
comprehensive genomic profiling (CGP)
liquid biopsy
Journal
Annals of oncology : official journal of the European Society for Medical Oncology
ISSN: 1569-8041
Titre abrégé: Ann Oncol
Pays: England
ID NLM: 9007735
Informations de publication
Date de publication:
28 Aug 2024
28 Aug 2024
Historique:
received:
28
06
2024
revised:
14
08
2024
accepted:
15
08
2024
medline:
31
8
2024
pubmed:
31
8
2024
entrez:
30
8
2024
Statut:
aheadofprint
Résumé
Emerging evidence supports tumor tissue-based comprehensive genomic profiling (CGP) in metastatic colorectal cancer (mCRC). Data on liquid biopsy-based circulating tumor DNA (ctDNA) CGP are scarce and mainly retrospective. Prospective comparison between the two tests is not currently available. The CAPRI 2-GOIM trial investigates efficacy and safety of ctDNA-driven, cetuximab-based, sequence of three treatment lines in patients with RAS/BRAF For 2/207 (0.96%) patients, no ctDNA was detected by F1L CDx. No patient displayed tumor fraction (TF) below 1%, whereas elevated ctDNA (TF≥10%) was detected among 140/205 (68.3%) patients. 1013 genomic variants were identified. F1L CDx found KRAS, NRAS or BRAF Baseline liquid biopsy-based CGP is feasible, it has high concordance with tumor tissue-based CGP, it could better recapitulate tumor heterogeneity, and it is clinically informative by identifying additional actionable genomic alterations in approximately half of RAS/BRAF
Sections du résumé
BACKGROUND
BACKGROUND
Emerging evidence supports tumor tissue-based comprehensive genomic profiling (CGP) in metastatic colorectal cancer (mCRC). Data on liquid biopsy-based circulating tumor DNA (ctDNA) CGP are scarce and mainly retrospective. Prospective comparison between the two tests is not currently available.
METHODS
METHODS
The CAPRI 2-GOIM trial investigates efficacy and safety of ctDNA-driven, cetuximab-based, sequence of three treatment lines in patients with RAS/BRAF
RESULTS
RESULTS
For 2/207 (0.96%) patients, no ctDNA was detected by F1L CDx. No patient displayed tumor fraction (TF) below 1%, whereas elevated ctDNA (TF≥10%) was detected among 140/205 (68.3%) patients. 1013 genomic variants were identified. F1L CDx found KRAS, NRAS or BRAF
CONCLUSION
CONCLUSIONS
Baseline liquid biopsy-based CGP is feasible, it has high concordance with tumor tissue-based CGP, it could better recapitulate tumor heterogeneity, and it is clinically informative by identifying additional actionable genomic alterations in approximately half of RAS/BRAF
Identifiants
pubmed: 39214459
pii: S0923-7534(24)03914-0
doi: 10.1016/j.annonc.2024.08.2334
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Investigateurs
Davide Ciardiello
(D)
Luca Boscolo Bielo
(LB)
Stefania Napolitano
(S)
Erika Martinelli
(E)
Teresa Troiani
(T)
Antonella Nicastro
(A)
Tiziana Pia Latiano
(TP)
Paola Parente
(P)
Evaristo Maiello
(E)
Antonio Avallone
(A)
Nicola Normanno
(N)
Salvatore Pisconti
(S)
Claudia Nisi
(C)
Roberto Bordonaro
(R)
Alessia Erika Russo
(AE)
Emiliano Tamburrini
(E)
Ilaria Toma
(I)
Claudio Lotesoriere
(C)
Simona Vallarelli
(S)
Maria Giulia Zampino
(MG)
Nicola Fazio
(N)
Giuseppe Curigliano
(G)
Fortunato Ciardiello
(F)
Giulia Martini
(G)
Sara Lonardi
(S)
Chiara Cremolini
(C)
Carlo Garufi
(C)
Pierosandro Tagliaferri
(P)
Giampaolo Tortora
(G)
Filippo Pietrantonio
(F)
Antonio Febbraro
(A)
Gerardo Rosati
(G)
Silvana Leo
(S)
Oronzo Brunetti
(O)
Rosanna Berardi
(R)
Saverio Cinieri
(S)
Mario Scartozzi
(M)
Alberto Zaniboni
(A)
Giancarlo Paoletti
(G)
Informations de copyright
Copyright © 2024 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.